Navigation Links
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
Date:11/8/2010

h fistulizing CD.  
  • Reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in patients with moderately to severely active UC who have had an inadequate response to conventional therapy.
  • Reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with PsA.  
  • Treatment of adult patients with chronic severe plaque PsO who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.

  • REMICADE is unique among available anti-TNF biologic therapies. It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE is a two-hour infusion administered every 4 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE patients may require as few as six treatments each year as maintenance therapy.

    IMPORTANT SAFETY INFORMATION FOR REMICADE

    Only your doctor can recommend a course of treatment after checking your health condition. REMICADE (infliximab) can cause serious side effects such as lowering your ability to fight infections. There are reports of serious infections caused by viruses, fungi or bacteria that have spread throughout the body, including tuberculosis (TB) and histoplasmosis. Some of these infections have been fatal. Your doctor should monitor you closely for signs and symptoms of TB during treatment with REMICADE.

    Unusual cancers have been reported in children and teenage patients taking TNF-blocker medicines. A rare form of fatal lymphoma has occurred mostly in teenage or young adult males with Crohn's disease or ulcerative colitis who were taking REMICADE and azathioprine or 6-mercaptopurine. For
    '/>"/>

    SOURCE Centocor Ortho Biotech, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
    2. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
    3. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
    4. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
    5. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
    6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
    10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
    11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... , July 31, 2014  Today, ... a new extension to its PageCenterX ® ... software is designed to provide downtime reporting capabilities ... outages. LRS is releasing the product for general ... environment, EMR applications experience outages for a variety ...
    (Date:7/31/2014)... CITY, Calif. , July 31, 2014  Genomic Health, ... company will host a conference call and webcast on Thursday, ... second quarter 2014 financial results.  The call and webcast will ... market close. Conference Call Details To access the ... Time via phone, please dial (877) 303-7208 from ...
    (Date:7/31/2014)... 31, 2014 Nutrastar International Inc. (OTCQB: NUIN; ... of premium branded consumer products, including commercially cultivated Cordyceps ... today announced the signing of its first distributor for ... to Hubei Province ... China . The contract with ...
    Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 2Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 3Genomic Health to Announce Second Quarter 2014 Financial Results and Host Conference Call on Thursday, August 7, 2014 4Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 2Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 3Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to Central China 4
    ... March 5 A study published by Deborah ... the Journal of Drugs in Dermatology ... resurfacing technologies, specifically, the SmartXide DOT(TM) laser. DOT utilizes ... for rapid healing, less downtime and profound results. Dr. ...
    ... Complications Reported With Coronary DeviceDOYLESTOWN, Pa., March 4 ... in February by completing the enrollment of 30 ... clinical trial for the vProtect(TM) Luminal Shield, conducted ... Shield successfully crossed all target lesions and was ...
    Cached Medicine Technology:New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation 2Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield 2
    (Date:7/31/2014)... NY (PRWEB) July 31, 2014 ... H2 2014, provides an overview of the Brain ... information on the therapeutic development for Brain Cancer, ... assessment by drug target, mechanism of action (MoA), ... with latest updates, and featured news and press ...
    (Date:7/31/2014)... July 31, 2014 Much of the liver,s metabolic ... body clock and UC Irvine researchers have now ... The study, published online today in Cell , ... metabolism and points the way to more focused drug ... obesity and diabetes. , Paolo Sassone-Corsi, UCI,s Donald Bren ...
    (Date:7/31/2014)... The virus that causes cold sores -- herpes simplex type ... according to a new study. Researchers in Australia ... infected with the virus. This explains why some people with ... them only occasionally. The authors said the findings could lead ... when the disease was dormant, it was a truce. It ...
    (Date:7/31/2014)... 31, 2014 i2i Systems announced today ... Inc. (SAS) to provide a robust patient referral ... SAS is one of the largest independent software companies ... than 40,000 patients are seen annually in its on-site ... delivering primary care, providers at the SAS HCC refer ...
    (Date:7/31/2014)... Over the past five years, the ... the estimated 151 million individuals that have required some ... of Ophthalmology (AAO). According to a Consumer Reports National ... vision correction surgery, a large share of consumers have ... medical procedure was to eliminate the use of glasses ...
    Breaking Medicine News(10 mins):Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Global Brain Cancer Market Size, Share, Analysis, Trends and Forecasts 2014 4Health News:Strict genomic partitioning by biological clock separates key metabolic functions 2Health News:Cold Sore Virus Active Without Symptoms, Study Finds 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Eye Surgery Clinics in the US Industry Market Research Report from IBISWorld Has Been Updated 3
    ... , , , ... e-Zassi.com(TM), an online decision support software system, integrated business ... has partnered with Medical Development Group (MDG), a medical device ... agreement, MDG will provide access to the e-Zassi platform to ...
    ... Aug. 12 Hank Oprinski, the CEO at Cap ... tour to inform corporations, chambers of commerce, golfing communities, economic clubs, universities ... , What did all the following businessmen have ... Tiger Woods) , Merv Griffin (TV Producer) , Tom Witter (Dean/Witter/Reynolds) , ...
    ... , , , ... today that its CardioVasc Advantage(TM) Vascular Reconstruction Device has been ... , "The technology of the Advantage VRD ... noted company Chairman, Eric P. Milledge. "The technical platform behind ...
    ... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
    ... , , LONDON, Aug. ... optimal and efficient way and, at the same time, adhere ... pharmacovigilance tools and technologies. , , (Logo: ... Frost & Sullivan ( http://www.healthcareIT.frost.com ), World Pharmacovigilance Markets ...
    ... ... A GPS navigation device allows you to most accurately ... above the Earth’s surface - instantly. This multi-perspective triangulation clearly leads ... performance measurement system incorporates a number of key vital signs from ...
    Cached Medicine News:Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 2Health News:Medical Development Group Partners with e-Zassi.com(TM) to Provide Members Access to Exciting New Software Tool 3Health News:September is Prostate Cancer Awareness Month 2Health News:Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device 2Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 2Health News:Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market 3Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 2Health News:Utilizing GPS-like Measurement Precision To More Accurately Determine Overall Performance 3
    ... MDS display system provides maximum impact for ... This unique approach to displaying frames allows ... and create appealing, flexible and eye-catching displays. ... and your patients are motivated. Removable holders. ...
    A pre-assembled, hexagonal, revolving tower display with two round 19.75" in diameter adjustable shelves. Enjoy 3.5 square feet of elegant shelf space for your products....
    A pre-assembled, rectangular shadow box/wall hanging display. It have 3 adjustable shelves with tempered glass, four 50 watt halogen top lights, laminated deck, dust resistant and electrical cord wit...
    Classic is proud to provide top-quality vision eyewear to physicians, health maintenance organizations (HMOs), and numerous state and federal government programs. Classic Laboratory produces over 150...
    Medicine Products: